Literature DB >> 24980027

The cancer genome: from structure to function.

Ad Geurts van Kessel1.   

Abstract

The 2014 joint meeting of the International Society for Cellular Oncology (ISCO) and the European Workshop on Cytogenetics and Molecular Genetics of Solid Tumors (EWCMST), organized by Nick Gilbert, Juan Cigudosa and Bauke Ylstra, was held from 11 to 14 May in Malaga, Spain. Since the previous meeting in 2012, the ever increasing availability of new sequencing technologies has enabled the analysis of cancer genomes at an increasingly greater detail. In addition to structural changes in the genome (i.e., translocations, deletions, amplifications), frequent mutations in important regulatory genes have been found to occur, as also frequent alterations in a large number of epigenetic factors. The challenge now is to relate structural changes in cancer genomes to the underlying disease mechanisms and to reveal opportunities for the design of novel (targeted) therapies. During the meeting, various topics related to these challenges and opportunities were addressed, including those dealing with functional genomics, genome instability, biomarkers and diagnostics, cancer genetics and epigenomics. Special attention was paid to therapy-driven cancer evolution (keynote lecture) and relationships between DNA repair, cancer and ageing (Prof. Ploem lecture). Based on the information presented at the meeting, several aspects of the cancer genome and its functional implications are provided in this report.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24980027     DOI: 10.1007/s13402-014-0177-5

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  52 in total

1.  Cancer. Taking a back door to target Myc.

Authors:  Gerard Evan
Journal:  Science       Date:  2012-01-20       Impact factor: 47.728

2.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

Review 3.  Pancreatic cancer genomics.

Authors:  David K Chang; Sean M Grimmond; Andrew V Biankin
Journal:  Curr Opin Genet Dev       Date:  2014-01-28       Impact factor: 5.578

Review 4.  The genetics of melanoma: recent advances.

Authors:  Victoria K Hill; Jared J Gartner; Yardena Samuels; Alisa M Goldstein
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-07-12       Impact factor: 8.929

Review 5.  Clinical application of circulating tumor cells in breast cancer.

Authors:  Leonie H A Broersen; Gabi W van Pelt; Rob A E M Tollenaar; Wilma E Mesker
Journal:  Cell Oncol (Dordr)       Date:  2013-11-19       Impact factor: 6.730

6.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

7.  Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Science       Date:  2014-03-28       Impact factor: 47.728

Review 8.  Research advances in esophageal diseases: bench to bedside.

Authors:  Massimiliano di Pietro; Rebecca C Fitzgerald
Journal:  F1000Prime Rep       Date:  2013-10-01

9.  A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization.

Authors:  Anand D Jeyasekharan; Yang Liu; Hiroyoshi Hattori; Venkat Pisupati; Asta Bjork Jonsdottir; Eeson Rajendra; Miyoung Lee; Elayanambi Sundaramoorthy; Simon Schlachter; Clemens F Kaminski; Yaara Ofir-Rosenfeld; Ko Sato; Jane Savill; Nabieh Ayoub; Ashok R Venkitaraman
Journal:  Nat Struct Mol Biol       Date:  2013-09-08       Impact factor: 15.369

10.  DNA damage leads to progressive replicative decline but extends the life span of long-lived mutant animals.

Authors:  H Lans; J M Lindvall; K Thijssen; A E Karambelas; D Cupac; O Fensgård; G Jansen; J H J Hoeijmakers; H Nilsen; W Vermeulen
Journal:  Cell Death Differ       Date:  2013-09-06       Impact factor: 15.828

View more
  13 in total

1.  E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells.

Authors:  Akhilesh Rawat; Gopal Gopisetty; Rajkumar Thangarajan
Journal:  Cell Oncol (Dordr)       Date:  2014-10-22       Impact factor: 6.730

2.  Validation of DNA promoter hypermethylation biomarkers in breast cancer--a short report.

Authors:  Jolien S de Groot; Xiaojuan Pan; Jan Meeldijk; Elsken van der Wall; Paul J van Diest; Cathy B Moelans
Journal:  Cell Oncol (Dordr)       Date:  2014-08-16       Impact factor: 6.730

3.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation.

Authors:  Yan Li; Kai Wang; Yi-Zhou Jiang; Xin-Wen Chang; Cai-Feng Dai; Jing Zheng
Journal:  Cell Oncol (Dordr)       Date:  2014-11-18       Impact factor: 6.730

4.  Somatic mutations of amino acid metabolism-related genes in gastric and colorectal cancers and their regional heterogeneity--a short report.

Authors:  Hye Rim Oh; Chang Hyeok An; Nam Jin Yoo; Sug Hyung Lee
Journal:  Cell Oncol (Dordr)       Date:  2014-12-02       Impact factor: 6.730

5.  ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma.

Authors:  Yanjie You; Wenjun Yang; Xin Qin; Fei Wang; Haijun Li; Canfeng Lin; Wenmei Li; Cunguo Gu; Yinpo Zhang; Yonggang Ran
Journal:  Cell Oncol (Dordr)       Date:  2015-02-24       Impact factor: 6.730

Review 6.  The bone marrow metastasis niche in retinoblastoma.

Authors:  Abbas Khosravi; Saeid Shahrabi; Mohammad Shahjahani; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-06-11       Impact factor: 6.730

7.  NFκB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy.

Authors:  Vignesh Ramesh; Karthikeyan Selvarasu; Jaishree Pandian; Soundarajan Myilsamy; Chidambaranathan Shanmugasundaram; Kumaresan Ganesan
Journal:  Cell Oncol (Dordr)       Date:  2016-08-25       Impact factor: 6.730

8.  Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system.

Authors:  Kristina Goetze; Christian G Fabian; Andrea Siebers; Livia Binz; Daniel Faber; Stefano Indraccolo; Giorgia Nardo; Ulrike G A Sattler; Wolfgang Mueller-Klieser
Journal:  Cell Oncol (Dordr)       Date:  2015-08-19       Impact factor: 6.730

9.  The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers.

Authors:  Raihana Maqbool; Rabiya Rashid; Rehana Ismail; Saif Niaz; Nisar Ahmad Chowdri; Mahboob Ul Hussain
Journal:  Cell Oncol (Dordr)       Date:  2015-09-03       Impact factor: 6.730

10.  MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1.

Authors:  Chao Yu; Min Wang; Zhipeng Li; Jie Xiao; Feng Peng; Xingjun Guo; Yazhu Deng; Jianxin Jiang; Chengyi Sun
Journal:  Cell Oncol (Dordr)       Date:  2015-02-10       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.